Abstract: Genetically-engineered cyanochrome fluorophore molecules (fluorophores) with increased fluorescence and with absorbing fluorescence in the blue and green (blue/green) portion of the light spectrum are provided. These fluorophores are derived from the domains of phytochromes, and in particular cyanobacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided.

Abstract: Carbon monoxide (CO) is a member of the gasotransmitter family that includes NO and H2S and is implicated in a variety of pathological and physiological conditions. Whereas exogenous therapeutic additions of CO to tissues and whole animals have been well studied, the real-time spatial and temporal tracking of CO at the cellular level remains an open challenge. We now report a new type of turn-on fluorescent probe for selective CO detection by exploiting palladium-mediated carbonylation reactivity. The compounds of the invention are capable of detecting CO both in aqueous buffer and in live cells with high selectivity over a range of biologically relevant reactive small molecules, providing a potentially powerful approach for interrogating its chemistry in biological systems.

Abstract: A novel reagent for clarification of an emulsion containing a salt and first and second surfactants is used in a method of clarifying emulsions which may contain inorganic, organic or biological particles to be measured. The reagent may be proved as kit of parts for in situ preparation thereof.

Abstract: It has been found that efficient screening for a compound having anticancer activity can be achieved by selecting a compound having activity to induce alternative autophagy using, as an index, formation of fluorescent bright spots due to aggregation of a lysosomal protein to which a fluorescent protein is attached in cells expressing the lysosomal protein.

Abstract: The current invention concerns a flow cytometric system and method for observing, analyzing and/or separating objects in a liquid sample, comprising a digital holographic microscope (DHM) and at least one fluidic system, whereby the DHM comprises illumination means, an interferometric system and digital recording means, whereby the fluidic system is capable of guiding said objects through an illumination beam of the illumination means of said DHM, whereby the fluidic system comprises a mechanism for inducing a liquid sample stream through the fluidic system, whereby preferably the fluidic system comprises a stream size controlling device for controlling the transverse dimensions of a liquid sample stream inside said fluidic system, preferably said stream size controlling device is capable of lining up the objects one-by-one or multiple objects at a time in said liquid sample stream.

Abstract: The invention relates to methods for differentiating progenitor cells into insulin producing pancreatic islet cells and compositions and methods for using such cells.

Abstract: The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

Abstract: The present invention relates to novel uses of compounds that protect the endothelium, particularly prostacyclin and variants and derivatives thereof in the treatment or prevention of acute traumatic coagulopathy (ATC) and of patients resuscitating from cardiac arrest. The invention also relates to a method of identifying individuals at risk of developing ATC.

Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing proliferative disorders, such as cancel-, that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include monotherapy with malate, or a derivative thereof, as well as combination therapy, such as malate, or a derivative thereof, combined with another therapeutic agent, such as a malic enzyme 2 inhibitor, an antineoplastic agent, a glycolysis inhibitor, an antiangiogenic agent, an immunomodulatory agent, an antibody, or a cytokine.

Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.

Abstract: The present disclosure is related to an interface device for providing access to a network to be monitored. The interface device includes a plurality of elements, the elements being sensors and/or actuators. A selection circuit is provided for selecting a subset of elements among the plurality of elements, each element of the subset being arranged for outputting and/or receiving a signal. A local memory is provided for storing the subset.

Abstract: A biological tissue processing substrate for fixing proteins in a biological tissue or degradation products of the proteins, the substrate comprising: a porous body that forms a contact surface with the biological tissue, the porous body holding in pores an enzyme for obtaining the proteins or the degradation products of the proteins from the biological tissue, wherein the proteins or the degradation products obtained by the action of the enzyme are brought into contact with a member consisting of a metal.

Abstract: A method for controlling an automated work cell which includes at least one robot arm having at least three degrees of freedom controlled according to a plurality of control axes; a control center; a device for controlling the robot arm which includes a plurality of motor controllers each controlling operation of one motor and suitable for operating at least one portion of the robot arm; and a communication bus between the control center and the device for controlling the robot arm; wherein the method includes steps of: a) sending instructions emitted by the control center to control the control axes to a single arithmetic unit belonging to the device for controlling the robot; b) determining, within the arithmetic unit and according to instructions received from the orders for each of the motors controlled by a motor controller; and c) sending each motor controller an order, determined in step b), for the motor controlled by each motor controller.

Abstract: The present invention relates to an apparatus that uses shadow images of cells to continuously measure cell activity at a high processing rate in order to provide cell activity and cell number results. According to one embodiment of the present invention, instead of a highly experienced examiner or technician using a microscope, ELISA reader, etc. having to collect various cell activity measurements and cell numbers, the collection of said information can be automated so as to reduce cost and largely reduce errors in measurements through the development of computer software coupled with hardware using low cost and compact optoelectronic components and simple image processing techniques.

Abstract: Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder.

Abstract: The present disclosure provides compositions and methods useful for molecular and cellular separation, detection and quantification. The compositions provided herein comprise a nanostructure having magnetic property operably linked to an analyte-binding member.

Abstract: A cell observation apparatus includes a cell recognition unit that recognizes a cellular region representing a cell from cell image data acquired by imaging the cell at a plurality of time points; and a cell parameter measurement unit that measures cell parameters characteristic of the cellular region recognized by the cell recognition unit. The apparatus also includes a cell viability determination unit that determines cell viability by comparing the cell parameters measured by the cell parameter measurement unit with thresholds.

Abstract: The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the Slc7a11 (NC_005101.2) gene, the Abcb1 (NC_005103.2) gene, etc. The present invention also provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene.

Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allodynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use.

Abstract: The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates.

Abstract: The current invention provides methods to identify ?9?2T-cell receptors (?9?2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the ?9-T-cell receptor chain and the ?2-T-Cell receptor chain (?2TCR chain) are of importance. Based on these findings, combinatorial-??TCR-chain-exchange (CTE) is proposed as an efficient method for identifying ?9?2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective ?9TCR and ?2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific ?9?2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the ?9?2TCRs according to the invention.

Abstract: A device comprising a housing and a cell block material, wherein the housing has a first end which is adapted to engage with sampling means via a gas tight fit, at least part of the cell block material is positioned within the housing such that, in use, the cell block material is in fluid connection with the sampling means, and the cell block material protrudes from the first end of the housing such that, in use, the cell block material extends into the sampling means.

Abstract: The bioassay process for the determination of alterations in neuronal connectivity and/or morphology comprises the operations of:—identifying the critical distance corresponding to which a pair of spaced single neuronal cells, subjected to the assay, is still able to form reciprocally interconnecting neuritic extensions, after a predetermined incubation period under conditions which favour the formation of such neuritic extensions, wherein each of said single neuronal cells is adhered to a respective spot of a substance promoting the adhesion of said neuronal cells, said spots being deposited at a distance from one another onto a substrate inhibiting the adhesion of neuronal cells, and—comparing the critical distance identified with the critical distance determined, under the same conditions, for reference cells, wherein a decrease in said critical distance for the neuronal cells subjected to the assay, relative to the critical distance for the reference cells, is indicative of an alteration in the neuronal c

Abstract: A tissue system includes: a support material; and a vascular network comprising a plurality of channels disposed in the support material. A method includes printing a bioink in a support structure to form a network of vascular precursor materials; and converting the vascular precursor materials into a physiologically relevant vascular network. Notably, the tissue systems, networks, etc. are physiologically-relevant, i.e. exhibiting one or more characteristics indicative of physiological relevance, such as a substantially fractal geometry, inter-vessel spacing, cellular composition, dermal structure, concentric multi-layered structure, etc.

Abstract: Devices for sorting components (e.g., cells) contained in a liquid sample are provided. In certain aspects, the devices include a magnetic separation device and an acoustic concentrator device fluidically coupled to magnetic separation device. Aspects of the invention further include methods for sorting cells in a liquid sample, and systems, and kits for practicing the subject methods.

Abstract: Provided herein are conjugate molecules containing a substrate for a nucleoside transport pathway linked to an active agent, wherein the conjugate can be transported into a cell or into the nucleus of a cell via a cellular nucleoside transport pathway. Further provided are methods of delivering a conjugate molecule to a target cell expressing a nucleoside transport pathway, wherein the conjugate contains a substrate for the nucleoside transport pathway linked to an active agent. Also provided are methods for screening for conjugates that are transported by nucleoside transport pathways. Further provided are methods of treating a patient having a disease or disorder affecting tissues expressing nucleoside transport pathways, in which a conjugate containing an agent effective in treating the disorder is administered to the patient. Also provided are methods of treating a patient having an autoimmune disorder involving administering to the patient a compound that inhibits a nucleoside transport pathway.

Abstract: Aspects of the present invention provide novel multi-targeted microbiological screening and monitoring methods having substantial utility for monitoring and control of microbial growth and contaminants, microbiological processes, predictive microbiology, and for exposure and risk assessment. Microbial markers shared by both target and index microbes are used in novel methods for microbial monitoring, monitoring of microbial performance potential, trend analysis, and statistical process control (SPC) in processes or systems that are receptive to a plurality of genetically distinct microbes.

Abstract: The present disclosure concerns a method for the identification of the presence or absence of cancer cells in a biological sample, more particularly a method for the identification of the susceptibility or resistance to a treatment with CD20 agonists of cancer cells in a biological sample, the methods including determining the level of expression of the gene Cyclon in the cells and comparing the level of expression to the level of expression in a non-cancer cell, wherein a level of expression higher than the level of expression in a non-cancer cell is an indication of the presence of a cancer cell, more particularly an indication of cancer cells with a resistance to treatment with antagonists. Kits for the determination of a level of expression of the Cyclon gene in a biological sample, a method for the identification of Cyclon expression antagonists, and methods for treating patients are provided.

Abstract: The present invention aims to develop and provide a method for identifying a disease associated with the abundance of TDP-43 in cells and a method for producing a TDP-43 binding inhibitor. By measuring the abundance of a measurement substance, the amount of binding between a measurement substance and TDP-43, etc. in cells obtained from a subject, it is identified whether or not the subject is suffering from a disease associated with the abundance of TDP-43 in cells. Also, a drug which can significantly reduce the binding between a measurement substance and TDP-43 is produced by adding a drug candidate substance.

Abstract: Systems and methods include directing limited frequencies of microwave signals toward target molecules, driving a motion of the target molecules to impact molecular recognition. In one implementation, a microwave spectra associated with the rotational modes of a target molecule is obtained. From peaks in the spectra, a mode of molecular movement is identified and a microwave signal profile is generated for driving a motion of binding portions of the molecule associated with the identified mode. Microwave signals are generated based on the signal profile for output by antennas. For example, the microwave signals can be can be used to impede the binding of quorum sensing molecules by receptors of P. aeruginosa. In one implementation, the antennas can be placed in a catheter for placement in a patient. In another implementation, the antennas can be placed in a sleeve or other device for use adjacent to the skin of a patient.

Abstract: The application discloses new biomarkers or test panels useful in systemic inflammatory conditions such as sepsis; methods for the diagnosis, prediction, prognosis and/or monitoring systemic inflammatory conditions such as sepsis based on measuring said biomarkers or test panels; and related kits and devices.

Abstract: In one aspect, a composition can include an organelle, and a nanoparticle having a zeta potential of less than ?10 mV or greater than 10 mV contained within the organelle. In a preferred embodiment, the organelle can be a chloroplast and the nanoparticle can be a single-walled carbon nanotube associated with a strongly anionic or strongly cationic polymer.

Abstract: Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.

Abstract: The disclosure relates to a system diagnosis of a disease or a disease condition whereby a single sample is prepared from a biological specimen which integrates synchronously the methods of protection, isolation and alteration of a biological specimen or a bio-molecule to isolate and study tissues and bio-molecules including DNA, large RNA, small RNA, protein, lipid, carbohydrates, and other metabolite simultaneously or individually resulting in a comprehensive understanding of the cause, prevention, risk, seriousness, confirmation, treatment, triage, and prognosis of a disease or a disease condition.

Abstract: A non-human transgenic animal having a polynucleotide encoding a PTN polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the PTN polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illnesses, particularly anxiety and depression, are disclosed.

Abstract: Methods and compositions for modifying fertility and/or spermatogenesis or spermiogenesis in a male mammalian subject involve administering to the subject or contacting the subject's testis cells, germ cells or sperm with a composition that modifies the activation, nucleic acid expression, protein expression, signaling or activity of one or more T1R3 receptors or an intermediate in the signaling pathways thereof in the subject's testis cells or germ cells. In another embodiment, the method further involves administering to the subject or contacting the subject's testis cells, germ cells or sperm with a composition that modifies the activation, nucleic acid expression, protein expression, signaling or activity of G-?-gustducin, or an intermediate in the signaling pathways thereof. Methods for screening a test molecule for its effect on spermatogenesis or spermiogenesis or fertility and compositions for modifying spermatogenesis or spermiogenesis or fertility in a mammalian subject, e.g.

Abstract: For efficient analysis of a protein-protein interaction, the present disclosure provides a kit for analyzing a protein-protein interaction, the kit including: a 1st expression vector including a 1st polynucleotide and a multi-cloning site, wherein, the 1st polynucleotide is operably linked to a promoter and encodes a 1st fusion protein having a 1st fluorescence protein and a 1st self-assembly protein, and the multi-cloning site is a site where a polynucleotide encoding a bait protein may be operably linked to the polynucleotide encoding the 1st fusion protein; and a 2nd expression vector including a 2nd polynucleotide and a multi-cloning site, wherein, the 2nd polynucleotide is operably linked to a promoter and encodes a 2nd fusion protein having a 2nd fluorescence protein and a 2nd self-assembly protein, and the multi-cloning site is a site where a polynucleotide encoding a prey protein may be operably linked to the polynucleotide encoding the 2nd fusion protein.

Abstract: The present invention relates to the treatment or prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical compositions comprising such an NKCC1 chloride co-transporter modulator as an active agent, a method for the treatment or prevention of tinnitus by administering such a chloride co-transporter modulator, and a screening method for the identification and characterization of compounds capable of modulating chloride co-transporter NKCC1.

Abstract: The present invention relates to the use of rosamine derivative compounds, as described herein, in detecting differentiated forms of a cell type of interest in a sample and in screening for compounds which inhibit differentiation of the cell type of interest.

Abstract: The invention relates to method of 13C-MR imaging and/or 13C-MR spectroscopy of cell death using an imaging medium which comprises hyperpolarized 13C-pyruvate.

Abstract: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial pH homeostasis and their use for inhibiting bacterial growth and treating a bacterial infection in a subject are also disclosed.

Abstract: The present invention provides methods for determining whether an agent facilitates the conversion of a cytoplasmic polyadenylation element binding (CPEB) protein from its non-prion form to its prion form. This invention also provides methods for determining the presence and amount of the prion form of CPEB protein in a cell. This invention also provides methods for facilitating the conversion of a non-prion CPEB protein to its prion form. This invention also provides an isolated prion form cytoplasmic polyadenylation element binding (CPEB) protein and compositions comprising a therapeutically effective amount of an agent that facilitates the conversion of CPEB protein from its non-prion form to its prion form, and methods of making such compositions.

Abstract: A concentration agent for capture of microorganisms, including diatomaceous earth bearing, on at least a portion of its surface, a surface treatment comprising a surface modifier comprising titanium dioxide, fine-nanoscale gold or platinum, or a combination thereof, and methods for making the concentration agent.

Abstract: A handheld diagnostic system may include a disposable sample holder for receiving and containing a biological sample and an analysis module having a chip-scale microscope. The sample holder may include a plurality of uniformly spaced tick marks. The analysis module may include a sensor for detecting the tick marks as the sample holder is inserted into the analysis module. The chip-scale microscope may include an image sensor for capturing images of the sample. Each time the sensor detects a tick mark, control circuitry may issue a control signal to the image sensor to capture an image of the biological sample. This type of automated image capture mechanism ensures that images are captured at a uniform spatial distribution even when the sample holder is inserted into the analysis module at variable speed. The analysis module may transmit sample imaging data to a portable electronic device.

Abstract: Container assembly including a container for storing a tissue sample and a cover adapted to engage with the container. The cover includes: a top member having a receptacle, a seal for sealing off the receptacle, a puncturing member for breaking the seal by displacement of the puncturing member. The container assembly has a first and a second position, wherein in the first position the container is isolated from the receptacle, and in the second position fluid communication is provided between the receptacle and the container. The container assembly includes a separator positioned between the seal and the bottom of the container, and the separator is provided with at least one aperture adapted to provide a fluid passage between the receptacle and the container.

Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.

Abstract: Provided are an apparatus for filtering a fluid, the apparatus including a first flow channel and a second flow channel which are connected to each other in a fluid communicable manner via a filtration medium, and a method of isolating particles using the apparatus.

Abstract: The present invention provides small molecules useful to affect cancer cells, along with related methods. The present compounds, formulations, kits and methods are useful for a variety of research, diagnostic and therapeutic purposes. STAT3 inhibitors, particularly LLL12, are disclosed. The STAT3 inhibitors are useful to treat breast cancer in general and breast cancer initiating cells in particular.

Abstract: According to one embodiment, a contrast agent includes a blood vessel contrast enhancement particles configured to enhance contrast of a blood vessel of an object and a diseased tissue contrast enhancement particles configured to enhance contrast of a diseased tissue of the object. The blood vessel contrast enhancement particles have a first particle size larger than a gap of vascular endothelial cells under an EPR effect. The diseased tissue contrast enhancement particles have a second particle size smaller than the gap.

Abstract: The present disclosure generally pertains to a method of facilitating the bioconversion of glycerol by microorganisms. In one embodiment, biodiesel derived crude glycerol is purified by removing fatty acids through acid precipitation. The fatty acid-free crude glycerol is then utilized as a carbon source for the culture of microorganisms and the production of value added substances. Additionally, the unsaturated fatty acids within the biodiesel-derived crude glycerol are converted to saturated fatty acids, allowing for fermentation behavior similar to that of pure glycerol. Both the cultured microorganisms and the culture media containing the purified crude glycerol may be analyzed for crude glycerol bioconversion products. The disclosure also relates to a method of increasing product yield through the addition of a second carbon source to the microorganism culture media.